These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

397 related items for PubMed ID: 17762500

  • 1. Use of rituximab in conjunction with immunosuppressive chemotherapy as a novel therapy for Epstein Barr virus-associated hemophagocytic lymphohistiocytosis.
    Balamuth NJ, Nichols KE, Paessler M, Teachey DT.
    J Pediatr Hematol Oncol; 2007 Aug; 29(8):569-73. PubMed ID: 17762500
    [Abstract] [Full Text] [Related]

  • 2. The role of rituximab in a case of EBV-related lymphoproliferative disease presenting with haemophagocytosis.
    Bosman G, Langemeijer SM, Hebeda KM, Raemaekers JM, Pickkers P, van der Velden WJ.
    Neth J Med; 2009 Sep; 67(8):364-5. PubMed ID: 19767670
    [No Abstract] [Full Text] [Related]

  • 3. Treatment of Epstein Barr virus-induced haemophagocytic lymphohistiocytosis with rituximab-containing chemo-immunotherapeutic regimens.
    Chellapandian D, Das R, Zelley K, Wiener SJ, Zhao H, Teachey DT, Nichols KE, EBV-HLH Rituximab Study Group.
    Br J Haematol; 2013 Aug; 162(3):376-82. PubMed ID: 23692048
    [Abstract] [Full Text] [Related]

  • 4. Bcl-2 antisense (G3139, Genasense) enhances the in vitro and in vivo response of Epstein-Barr virus-associated lymphoproliferative disease to rituximab.
    Loomis R, Carbone R, Reiss M, Lacy J.
    Clin Cancer Res; 2003 May; 9(5):1931-9. PubMed ID: 12738752
    [Abstract] [Full Text] [Related]

  • 5. Epstein-Barr virus-induced lymphoproliferative disorder after rituximab combined with CHOP therapy.
    Johnston A, Salles G, Espinouse D, Felman P, André P, Berger F, Coiffier B.
    Clin Lymphoma Myeloma; 2008 Dec; 8(6):356-8. PubMed ID: 19064401
    [Abstract] [Full Text] [Related]

  • 6. Epstein-Barr virus-induced hemophagocytic lymphohistiocytosis and X-linked lymphoproliferative disease: a mimicker of sepsis in the pediatric intensive care unit.
    Mischler M, Fleming GM, Shanley TP, Madden L, Levine J, Castle V, Filipovich AH, Cornell TT.
    Pediatrics; 2007 May; 119(5):e1212-8. PubMed ID: 17403820
    [Abstract] [Full Text] [Related]

  • 7. Epstein barr virus hemophagocytic lymphohistiocytosis related to rituximab use and immunopathogenetic insights.
    Papageorgiou SG, Tsiodras S, Siakallis G, Bazani E, Spathis A, Poulakou G, Korkolopoulou P, Panayiotides I, Pappa V.
    Pathol Res Pract; 2016 Dec; 212(12):1194-1198. PubMed ID: 28340951
    [Abstract] [Full Text] [Related]

  • 8. Microbiological findings and treatment of EBV-associated hemophagocytic lymphohistiocytosis: a case report.
    Przybylski M, Dzieciatkowski T, Zduńczyk D, Jedrzejczak WW, Luczak M.
    Arch Immunol Ther Exp (Warsz); 2010 Jun; 58(3):247-52. PubMed ID: 20383798
    [Abstract] [Full Text] [Related]

  • 9. [Clinical features and outcome analysis of 83 childhood Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis with HLH-2004 protocol].
    Xiao L, Xian Y, Dai BT, Su YC, Xiao JW, Zheng QC, Zhao XD, Yu J.
    Zhonghua Xue Ye Xue Za Zhi; 2011 Oct; 32(10):668-72. PubMed ID: 22339824
    [Abstract] [Full Text] [Related]

  • 10. [Two young adult cases of Epstein-Barr virus associated-hemophagocytic lymphohistiocytosis with monoclonal proliferation of virus-infected cells within a short period after primary infection].
    Idutsu K, Abe Y, Matsushima T, Sada E, Ohtsuka R, Kiyasu J, Shiratsuchi M, Kotoh K, Nishimura J, Ohga S, Takayanagi R.
    Rinsho Ketsueki; 2008 Nov; 49(11):1541-7. PubMed ID: 19047785
    [Abstract] [Full Text] [Related]

  • 11. Sustained response to intrathecal rituximab in EBV associated Post-transplant lymphoproliferative disease confined to the central nervous system following haematopoietic stem cell transplant.
    Bonney DK, Htwe EE, Turner A, Kelsey A, Shabani A, Hughes S, Hughes I, Wynn RF.
    Pediatr Blood Cancer; 2012 Mar; 58(3):459-61. PubMed ID: 21584931
    [Abstract] [Full Text] [Related]

  • 12. Epstein-Barr Virus (EBV)-induced B-cell Lymphoproliferative Disorder Mimicking the Recurrence of EBV-associated Hemophagocytic Lymphohistiocytosis.
    Yatsushiro Y, Nishikawa T, Saito A, Nakazawa Y, Imadome KI, Nakagawa S, Kodama Y, Okamoto Y, Kanegane H, Kawano Y.
    J Pediatr Hematol Oncol; 2019 Jan; 41(1):e44-e46. PubMed ID: 29324572
    [Abstract] [Full Text] [Related]

  • 13. Infection of T lymphocytes in Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis in children of non-Asian origin.
    Beutel K, Gross-Wieltsch U, Wiesel T, Stadt UZ, Janka G, Wagner HJ.
    Pediatr Blood Cancer; 2009 Aug; 53(2):184-90. PubMed ID: 19353621
    [Abstract] [Full Text] [Related]

  • 14. Treatment choice of immunotherapy or further chemotherapy for Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis.
    Shiraishi A, Ohga S, Doi T, Ishimura M, Takimoto T, Takada H, Miyamoto T, Abe Y, Hara T.
    Pediatr Blood Cancer; 2012 Aug; 59(2):265-70. PubMed ID: 22183955
    [Abstract] [Full Text] [Related]

  • 15. Epstein-Barr virus-associated lymphoproliferation awareness in hemophagocytic syndrome complicating thiopurine treatment for Crohn's disease.
    Serrate C, Silva-Moreno M, Dartigues P, Poujol-Robert A, Sokol H, Gorin NC, Coppo P.
    Inflamm Bowel Dis; 2009 Oct; 15(10):1449-51. PubMed ID: 19177429
    [No Abstract] [Full Text] [Related]

  • 16. Acute promyelocytic leukemia following chemotherapy for EBV-associated hemophagocytic lymphohistiocytosis.
    Sathiyamoorthy S, Shad A, Ozdemirli M.
    Pediatr Blood Cancer; 2011 May; 56(5):850-2. PubMed ID: 21370422
    [Abstract] [Full Text] [Related]

  • 17. [Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis subsequent to rabbit antithymocyte globulin administration and successfully treated with rituximab in a patient with aplastic anemia].
    Nagata H, Fujino T, Muramatsu A, Kawaji Y, Kuriyama K, Oshiro M, Hirakawa Y, Iwai T, Uchiyama H.
    Rinsho Ketsueki; 2018 May; 59(4):407-413. PubMed ID: 29743400
    [Abstract] [Full Text] [Related]

  • 18. Pathogenesis and mechanism of disease progression from hemophagocytic lymphohistiocytosis to Epstein-Barr virus-associated T-cell lymphoma: nuclear factor-kappa B pathway as a potential therapeutic target.
    Chuang HC, Lay JD, Hsieh WC, Su IJ.
    Cancer Sci; 2007 Sep; 98(9):1281-7. PubMed ID: 17627615
    [Abstract] [Full Text] [Related]

  • 19. [Hemophagocytic lymphohistiocytosis and Epstein-Barr virus infection in children].
    Darteyre S, Ludwig C, Jeziorski E, Schved JF, Rodière M.
    Med Mal Infect; 2010 Jan; 40(1):18-26. PubMed ID: 19836912
    [Abstract] [Full Text] [Related]

  • 20. Severe hemorrhagic coagulopathy with hemophagocytic lymphohistiocytosis secondary to Epstein-Barr virus-associated T-cell lymphoproliferative disorder.
    Nawathe PA, Ravindranath TM, Satwani P, Baird JS.
    Pediatr Crit Care Med; 2013 May; 14(4):e176-81. PubMed ID: 23439459
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 20.